Dr. Ma is an Associate Professor in the Department of Pharmaceutical Sciences and a member of the Center for Pharmacogenetics, University of Pittsburgh School of Pharmacy. He obtained his Ph.D. in Pharmacology and Toxicology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2003. From there, he went to National Institutes of Health (NIH) and completed his postdoctoral training in Dr. Frank J. Gonzalez’s laboratory in 2008. Afterward, he worked as an Assistant Professor at University of Kansas Medical Center, until he joined the University of Pittsburgh in 2013.
Dr. Ma’s research interest includes nuclear receptors, drug-drug interactions, drug-induced liver injury, toxicometabolomics, and personalized medicine.
(1). Sachar M, Li F, Liu K, Wang P, Lu J, Ma X. Chronic Treatment with Isoniazid Causes Protoporphyrin IX Accumulation in Mouse Liver. Chem Res Toxicol. 2016 Aug 15;29(8):1293-7. doi: 10.1021/acs.chemrestox.6b00121. Epub 2016 Aug 2. PubMed PMID: 27438535; PubMed Central PMCID: PMC5316289.
(2). Li F, Wang P, Liu K, Tarrago MG, Lu J, Chini EN, Ma X. A High Dose of Isoniazid Disturbs Endobiotic Homeostasis in Mouse Liver. Drug Metab Dispos. 2016 Nov;44(11):1742-1751. Epub 2016 Aug 16. PubMed PMID: 27531952; PubMed Central PMCID: PMC5074471.
(3). Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016 Sep;6(5):384-392. Epub 2016 Aug 3. Review. PubMed PMID: 27709007; PubMed Central PMCID: PMC5045547.
(4). He H, Nie YL, Li JF, Meng XG, Yang WH, Chen YL, Wang SJ, Ma X, Kan QC, Zhang LR. Developmental regulation of CYP3A4 and CYP3A7 in Chinese Han population. Drug Metab Pharmacokinet. 2016 Dec;31(6):433-444. doi: 10.1016/j.dmpk.2016.08.008. Epub 2016 Sep 9. PubMed PMID: 27727071.
(5). Chen Y, Xia R, Huang Y, Zhao W, Li J, Zhang X, Wang P, Venkataramanan R, Fan J, Xie W, Ma X, Lu B, Li S. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443. doi: 10.1038/ncomms13443. PubMed PMID: 27819653; PubMed Central PMCID: PMC5103075.
(6). Shehu AI, Ma X, Venkataramanan R. Mechanisms of Drug-Induced Hepatotoxicity. Clin Liver Dis. 2017 Feb;21(1):35-54. doi: 10.1016/j.cld.2016.08.002. Review. PubMed PMID: 27842774.
(7). Yan L, Liu J, Zhao Y, Nie Y, Ma X, Kan Q, Zhang L. Suppression of miR-628-3p and miR-641 is involved in rifampin-mediated CYP3A4 induction in HepaRG cells. Pharmacogenomics. 2017 Jan;18(1):57-64. doi: 10.2217/pgs-2016-0088. Epub 2016 Dec 14. PubMed PMID: 27967330.
(8). Xu J, Zhang X, Chen Y, Huang Y, Wang P, Wei Y, Ma X, Li S. Improved Micellar Formulation for Enhanced Delivery for Paclitaxel. Mol Pharm. 2017 Jan 3;14(1):31-41. doi: 10.1021/acs.molpharmaceut.6b00581. Epub 2016 Nov 30. PubMed PMID: 28043124.
(9). Zeng H, Jiang Y, Chen P, Fan X, Li D, Liu A, Ma X, Xie W, Liu P, Gonzalez FJ, Huang M, Bi H. Schisandrol B protects against cholestatic liver injury through pregnane X receptors. Br J Pharmacol. 2017 Apr;174(8):672-688. doi: 10.1111/bph.13729. Epub 2017 Mar 16. PubMed PMID: 28128437; PubMed Central PMCID:PMC5368048.
(1). “Applications of Metabolomics in Medical Laboratory”. The 5th Oriental Congress of Laboratory Medicine. Shanghai, China, 2016.
(2). “Metabolomic applications to guide the mechanistic understanding of drug-induced liver injury (DILI)”. The 21st International Symposium on Microsomes and Drug Oxidations. Davis, CA, 2016.
(3). “The Gut-liver Axis in Eythropoietic Protoprophyria”. ASPET Annual Meeting at Experimental Biology. Chicago, IL, 2017
Ongoing Research Support
• R01DK090305, NIDDK/NIH, 2012-2018. Mechanisms of adverse effects of anti-tuberculosis drugs. PI: Xiaochao Ma.
• R01GM118367, NIGMS/NIH, 2016-2020. Short- or long-term impacts of drug exposure at early life on drug metabolism, therapeutic efficacy, and drug-induced toxicity. PI: Xiaobo Zhong. Role of Xiaochao Ma: Co-I.
• R01AI131983, NIAID/NIH, 2017-2022. Pharmacoenhancers for antiretroviral therapy: safety and future development. PI: Xiaochao Ma.